Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Actinogen Medical Limited ( (AU:ACW) ) has provided an update.
Actinogen Medical announced the publication of a peer-reviewed article in the Clinical Pharmacology in Drug Development journal, which supports the use of a 10 mg daily dose of Xanamem for treating central nervous system diseases. This journal publication confirms the effectiveness of Xanamem in inhibiting the target enzyme at lower doses, reinforcing the company’s confidence in the ongoing clinical trials for Alzheimer’s and Depression. The study highlights the drug’s potential in improving cognitive function, with significant implications for stakeholders as the trials progress and results are anticipated in the coming years.
More about Actinogen Medical Limited
Actinogen Medical Limited is an ASX-listed biotechnology company focused on developing a novel therapy for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol, such as Alzheimer’s Disease and Depression. Their lead compound, Xanamem, aims to control cortisol levels in the brain, with potential applications in treating a range of cognitive dysfunctions and psychiatric conditions.
YTD Price Performance: 50.0%
Average Trading Volume: 455,050
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $56.81M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.
